Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin and Palliative Radiotherapy in Extensive Stage Small Cell Lung Cancer
NCT05244239Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Jul 2022
- Primary completion
- Jul 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lurbinectedin in small cell lung cancer (SCLC), sponsored by Emory University. Primary endpoint: Incidence of adverse events of palliative radiotherapy with lurbinectedin at 1 year. Started Jul 2022; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05244239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244239.